We are developing genetically engineered toxoid vaccines and therapeutic monoclonal antibodies against Shiga toxin-producing Escherichia coli (STEC, e.g., O157:H7) infection.

We are also interested in the development of virus-like particle (VLP) vaccines against viral infection. VLP vaccines are expressed in E. coli and Bombyx mori with recombinant protein technology. VLP is non-infectious and a promising vaccine antigen since VLP contains only viral outer shell, not genetic materials.

We conduct our research activities in collaboration with industrial and governmental sectors.

  • 図1. 志賀毒素産生性大腸菌に対するトキソイドワクチン開発
    図1. 志賀毒素産生性大腸菌に対するトキソイドワクチン開発
    STECが産生するStxに対する試作トキソイドワクチンを評価した結果(Stx攻撃後のマウスの生存率) 、Stx2(2型志賀毒素)のB鎖のみ、5量体結束分子(COMP)との融合化が必須で、Stx1 (1型志賀毒素)のB鎖には不要であることが明らかになった。
  • 図2. VLP電子顕微鏡写真
    図2. VLP電子顕微鏡写真


Position Name
Professor Takeshi ARAKAWA
Assistant Prof. Yukihiro TAMAKI